Rebecca Kristeleit

Rebecca Kristeleit at University College London Hospitals specializes in gynecologic cancers with particular expertise in PARP inhibitor therapy including rucaparib in BRCA-mutated ovarian cancer. She has contributed to registrational trials for rucaparib and to studies of PARP inhibitor resistance mechanisms in platinum-resistant settings. Her translational work bridges genomics with clinical outcomes in ovarian cancer. She is active in early-phase trial design and international gynecologic oncology research networks.